Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 53 (2), 203-5

Treatment of an Infant With Severe Acute Refractory Immune Thrombocytopenic Purpura Using Combination Therapy Including Rituximab

Affiliations
Case Reports

Treatment of an Infant With Severe Acute Refractory Immune Thrombocytopenic Purpura Using Combination Therapy Including Rituximab

Kotoe Iesato et al. Pediatr Blood Cancer.

Abstract

Some infants with acute immune thrombocytopenic purpura (ITP) do not respond to first-line therapy, and currently there is no consensus on therapy for these refractory cases. We describe a 12-week-old infant with acute ITP who was unresponsive to intravenous immunoglobulin and corticosteroid, and developed gastrointestinal bleeding. Several combination therapies were unsuccessful. After four doses of rituximab followed by intravenous immunoglobulin and corticosteroid, his platelet counts gradually increased. Combined therapy which includes rituximab may be a promising treatment for severe acute refractory ITP.

Similar articles

See all similar articles

Cited by 2 articles

Publication types

MeSH terms

LinkOut - more resources

Feedback